Ligand Pharmaceuticals Inc (LGND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Ligand Pharmaceuticals Inc (LGND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH59641D
  • |
  • Pages: 111
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company provides a diversified portfolio of biotechnology and pharmaceutical products. Its marketed product portfolio encompasses indication for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand's clinical development portfolio comprises medications targeted at the treatment of seizure, cancer, diabetes, coma, cardiovascular disease, liver disease, muscle wasting, kidney disease, and others. In partnership with other pharmaceutical companies the company also offers late-stage development, regulatory management and commercialization support. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc (LGND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 20

Asset Purchase 20

Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 20

Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To USD4.5 Million 21

Venture Financing 22

Nucorion Pharma Raises USD5 Million in Series A Venture Financing 22

Partnerships 23

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 23

Symphogen Enters Into Agreement With Open Monoclonal Technology 24

Open Monoclonal Expands Agreement with CNA Development 24

Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25

Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 26

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 27

Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 27

Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 28

Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 29

WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 30

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 31

Licensing Agreements 32

Amgen Enters into Licensing Agreement with Ligand Pharma 32

Surface Oncology Enters into Licensing Agreement with Ligand Pharma 33

xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 33

Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 34

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 35

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 35

Novartis Enters into Licensing Agreement with Ligand Pharma 36

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 37

Open Monoclonal Enters into Licensing Agreement with University of Nottingham 38

Open Monoclonal Enters into Licensing Agreement with Celgene 39

Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 39

Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 40

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 41

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 42

Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 43

TeneoBio Enters into Licensing Agreement with Ligand Pharma 44

Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 45

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 46

ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 46

Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 47

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 48

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 49

RODES Enters into Licensing Agreement with Ligand Pharma 49

Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 50

Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 51

ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 52

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 52

Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 53

Sanofi Enters into Licensing Agreement with Ligand Pharma 54

Open Monoclonal Enters into Licensing Agreement with Amgen 55

HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 55

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 56

Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 57

Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 58

Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 59

Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 60

Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 61

Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 62

Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 63

Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 64

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 65

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 65

Ligand Pharma Enters Into Licencing Agreement With Merck 66

Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist 67

Ligand Pharma Enters Into Licensing Agreement With Hospira 68

Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 69

Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 70

Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 71

Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 72

Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 74

Equity Offering 75

Ligand Pharma Completes First Tranche Of Public Offering Of Securities For USD2.7 Million 75

Ligand Pharma Announces Private Placement Of Common Stock For USD30 Million 76

Debt Offering 77

Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 77

Acquisition 78

Ligand Pharma to Acquire Open Monoclonal Technology for USD178 Million 78

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 79

Ligand Pharma Acquires CyDex Pharma 80

Ligand Pharmaceuticals Inc-Key Competitors 83

Key Employees 84

Locations And Subsidiaries 85

Head Office 85

Other Locations & Subsidiaries 85

Recent Developments 87

Financial Announcements 87

May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 87

Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 90

Nov 03, 2016: Ligand Reports Third Quarter 2016 Financial Results 93

Aug 04, 2016: Ligand Reports Second Quarter 2016 Financial Results 96

May 04, 2016: Ligand Reports First Quarter 2016 Financial Results 99

Feb 10, 2016: Ligand Reports Fourth Quarter and Full Year 2015 Financial Results 102

Clinical Trials 105

Feb 27, 2017: Enrollment Completed in Ligand's Phase 2 Trial of LGD-6972 in Type 2 Diabetes 105

Sep 13, 2016: Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes 106

Aug 15, 2016: Results from Phase 1 Trials with Ligand LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism 107

Other Significant Developments 109

Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 109

Appendix 111

Methodology 111

About GlobalData 111

Contact Us 111

Disclaimer 111

List of Figures

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13

List of Tables

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Ligand Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 20

Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To USD4.5 Million 21

Nucorion Pharma Raises USD5 Million in Series A Venture Financing 22

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 23

Symphogen Enters Into Agreement With Open Monoclonal Technology 24

Open Monoclonal Expands Agreement with CNA Development 24

Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25

Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 26

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 27

Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 27

Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 28

Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 29

WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 30

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 31

Amgen Enters into Licensing Agreement with Ligand Pharma 32

Surface Oncology Enters into Licensing Agreement with Ligand Pharma 33

xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 33

Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 34

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 35

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 35

Novartis Enters into Licensing Agreement with Ligand Pharma 36

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 37

Open Monoclonal Enters into Licensing Agreement with University of Nottingham 38

Open Monoclonal Enters into Licensing Agreement with Celgene 39

Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 39

Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 40

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 41

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 42

Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 43

TeneoBio Enters into Licensing Agreement with Ligand Pharma 44

Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 45

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 46

ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 46

Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 47

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 48

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 49

RODES Enters into Licensing Agreement with Ligand Pharma 49

Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 50

Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 51

ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 52

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 52

Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 53

Sanofi Enters into Licensing Agreement with Ligand Pharma 54

Open Monoclonal Enters into Licensing Agreement with Amgen 55

HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 55

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 56

Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 57

Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 58

Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 59

Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 60

Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 61

Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 62

Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 63

Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 64

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 65

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 65

Ligand Pharma Enters Into Licencing Agreement With Merck 66

Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist 67

Ligand Pharma Enters Into Licensing Agreement With Hospira 68

Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 69

Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 70

Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 71

Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 72

Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 74

Ligand Pharma Completes First Tranche Of Public Offering Of Securities For USD2.7 Million 75

Ligand Pharma Announces Private Placement Of Common Stock For USD30 Million 76

Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 77

Ligand Pharma to Acquire Open Monoclonal Technology for USD178 Million 78

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 79

Ligand Pharma Acquires CyDex Pharma 80

Ligand Pharmaceuticals Inc, Key Competitors 83

Ligand Pharmaceuticals Inc, Key Employees 84

Ligand Pharmaceuticals Inc, Subsidiaries 85

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ligand Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16235
Site License
USD 500 INR 32470
Corporate User License
USD 750 INR 48705

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com